Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT05500846

Targeted Cryoablation of Prostate Cancer Lesions: An Investigator-initiated Trial

Sponsor: Osamu Ukimura

View on ClinicalTrials.gov

Summary

This clinical trial is to provide a minimally invasive treatment option in which the targeted prostate cancer tissue is killed by cryoablation at extremely low temperatures only in the specific area of cancer "that should be treated for saving of life"; while, leaving a portion of the normal prostate tissue that is not cancerous. It is a treatment, named by "focal therapy" for "clinically localized prostate cancer". As this new treatment is aiming to treat only specific prostatic area of cancer, it is different from the invasive conventional treatment to remove the entire prostate gland. The goal is to achieve both to control of known cancer by treating only the cancerous area and to maintain of QOL (Quality-of-life) by leaving of the other normal prostate tissue and its surrounding organs intact resulting in prevention of urinary-leakage and sexual-dysfunction as the complications.

Key Details

Gender

MALE

Age Range

20 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2021-10-19

Completion Date

2024-12-31

Last Updated

2024-06-21

Healthy Volunteers

Conditions

Prostate Cancer

Interventions

DEVICE

The Visual Ice Cryoablation System

Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.

Inclusion Criteria: 1. Patients who have a PI-RADS category 3 or 4 lesion on MRI image at enrollment and who have a single lesion with a Gleason score 7 or 8 on histopathology of the prostate needle biopsy at enrollment; or, patients who have a PI-RADS category 4 or 5 lesion on MRI image at enrollment and who have a single lesion with a Gleason score 6 or 7 on histopathology of the prostate needle biopsy at enrollment 2. Patients with prostate cancer that is clinical stage T2c or lower (T1a-T2cN0M0) according to the TNM Classification as determined during enrollment 3. Patients between the ages of 20 and 85 when providing consent to participate in this trial 4. Patients from whom consent is obtained prior to enrollment in this trial Exclusion Criteria: 1. Patients to have a lesion identified as PI-RADS category 4 or 5 on MRI images at enrollment and who have a single lesion with a diameter of less than 10 mm and Gleason score of 6 on the histopathology of the prostate needle biopsy at enrollment (the lesion is referred to as "non-target lesions") (the diameter of the lesion is defined as the longer one of the lesion diameter identified on MRI images at enrollment or the tumor length as measured on histopathology of prostate needle biopsy) 2. Patients to have 4 or more non-target lesions (non-target lesions are defined as the lesions defined in exclusion criterion 1, or lesions with PI-RADS category 3 on MRI image at enrollment and Gleason score 6 on biopsy at enrollment) 3. Patients to have a lesion with PI-RADS category 5 on MRI image at enrollment and Gleason score 8 on histopathology of prostate needle biopsy at enrollment (the lesion is referred "excluded lesions") 4. Patients with a serum prostate-specific antigen (PSA) level over 20 ng/ml during enrollment 5. Patients in whom the distance from the target prostate cancer lesion to an external urinary sphincter is 5 mm or less on MRI images (coronal or sagittal) obtained during enrollment 6. Patients who have undergone surgery, drug therapy, or radiation therapy for prostate cancer prior to enrollment 7. Patients who have received an antiandrogen for benign prostatic hyperplasia prior to enrollment 8. Patients using absorbent pads or adult diapers due to urge incontinence 9. Patients with active multiple cancers 10. Patients for whom MRI scans are contraindicated 11. Patients in whom transrectal ultrasound cannot be performed for some reason, such as a constricted rectum 12. Patients with a prothrombin time\<50% or platelet count\<60,000/mm3 during enrollment 13. Patients deemed to be ineligible by an investigator

Locations (2)

University Hospital, Kyoto Prefectural University of Medicine

Kyoto, Japan

Kyoto Miniren Chuo Hospital